The soaring demand for Ozempic and other GLP-1 drugs is creating a major financial challenge for public health systems, insurers, and government programs. As these medications become more widely used, their high costs are forcing policymakers to confront difficult questions about access, coverage, and long-term spending.
This episode explores why GLP-1 drugs are putting pressure on public budgets, how governments are responding, and what the debate means for patients, taxpayers, drugmakers, and the future of healthcare financing.
Podcast: Play in new window | Download
